2022 will see pharma target nutraceutical products: CPhI Report

2022-will-see-pharma-target-nutraceutical-products-cphi-report
image credit- shutterstock

2025 forecast: massive growth expected in consumer-friendly dosages using natural ingredients for proactive & pre-emptive health

CPhI Worldwide has released the final part of its annual report with far reaching predictions for 2022 and beyond into 2025 for the nutraceuticals market.

The findings explore the long-term trends underway in the global nutraceutical industry, with consumers predicted to increase spending on natural products and sustainable formulations that can offer ‘preventative or proactive’ health benefits.

Consequentially, it is likely we will see pharma companies increasingly introducing nutraceutical formulations and forming strategic partnerships with CDMOs to develop new products. 

The report was made by CPhI’s nutraceutical experts from SIRIO pharma and suggests that consumer-friendly dosage forms – such as gummies and softgels – that can be made with natural ingredients and supportable health claims, will see rapid growth. 

The report predicts that the most successful launches are likely to be from brands with well-developed marketing strategies and products that closely align with adjacent offerings.

Another global trend predicted to accelerate over the next 2-3 years is for natural alternatives to help boost mind, mood and wellness. For example, we are seeing ashwagandha as one of the most popular adaptogens globally with recent clinical trials supporting its anti-stress and sleep-promoting effects.

 

Read Previous

BL Agro launches Nourish store in Ayodhya

Read Next

71.9% households consume adequately iodised salt: Govt survey

Leave a Reply